What Are The Primary Absolute And Relative Contraindications To Screen For Prior To Performing Ablative Fractional Laser Resurfacing? Key Exclusions And Cautions

The primary absolute contraindication is a history of facial keloid scarring. Relative contraindications requiring postponement, modification, or specialist assessment include active infection in the treatment area, koebnerizing disorders such as vitiligo or psoriasis, systemic vasculitis, immunosuppression, prior radiation at the treatment site, and recent systemic oral retinoid use.

Screen first for abnormal scarring risk, impaired healing, active infection, and conditions that may worsen with skin injury. When these risks are present, defer treatment or use a modified protocol rather than proceeding routinely.

Absolute Contraindications

History of facial keloid scarring

A history of facial keloid formation is the clearest absolute contraindication because ablative resurfacing can provoke excessive scar formation.

A history of hypertrophic scarring is generally treated as a major caution and may be considered a contraindication depending on its severity, location, and the clinician’s protocol.

Important protocol-dependent exclusions

Some references classify the following as absolute rather than relative contraindications:

Active bacterial, viral, or fungal infection in the treatment area.
Current or recent systemic isotretinoin or other oral retinoid use, commonly within the prior 6–12 months.
Inability or unwillingness to follow postoperative wound-care and sun-protection instructions.

These patients should generally not undergo ablative resurfacing until the infection has resolved, the retinoid interval is appropriate, or reliable postoperative adherence is established.

Relative Contraindications

Active infection in the treatment zone

Active infection should normally lead to deferral until adequately treated and resolved. Ablation disrupts the epidermal barrier and can worsen infection or facilitate dissemination.

A history of herpes simplex is not usually a contraindication, but it requires antiviral prophylaxis, particularly for full-face or perioral treatment.

Vitiligo and psoriasis

A history of vitiligo or psoriasis creates a risk of Koebnerization, in which cutaneous trauma induces new lesions at the treatment sites.

Treatment should be avoided during active or unstable disease and considered cautiously when the condition is well controlled.

Systemic vasculitis and connective-tissue disease

Systemic vasculitis and active collagen vascular disorders may impair healing or increase inflammatory complications.

Patients with conditions such as active lupus or scleroderma require individualized medical assessment; active or severe disease may warrant exclusion.

Active immunosuppression

Immunosuppression can increase the risk of:

Delayed re-epithelialization.
Bacterial, viral, or fungal infection.
Poor wound healing.
Abnormal scarring.

The underlying disease, medication regimen, degree of immunosuppression, and treatment area should be reviewed before proceeding.

Prior radiation therapy to the treatment site

Previously irradiated skin may have reduced vascularity, altered adnexal structures, and impaired regenerative capacity.

Ablative treatment over irradiated tissue should be approached conservatively or avoided, depending on the extent and recency of radiation injury.

Recent systemic oral retinoid use

Recent isotretinoin or related oral retinoid therapy is commonly treated as a relative or absolute contraindication, depending on the protocol.

Because published recommendations vary between approximately 6 and 12 months, the prescribing history and the specific laser protocol should be reviewed before treatment.

Additional Risk Factors to Assess

Darker phototypes and prior dyschromia

Fitzpatrick skin types IV–VI and a history of post-inflammatory hyperpigmentation increase the risk of prolonged hyperpigmentation or hypopigmentation.

These factors do not automatically prohibit treatment, but they support conservative settings, careful counseling, strict photoprotection, and sometimes a test spot.

Pregnancy and breastfeeding

Pregnancy and breastfeeding are generally treated as relative contraindications or reasons to defer elective resurfacing because safety data and medication choices for peri-procedural care may be limited.

The risk–benefit assessment should include the patient’s obstetric clinician when treatment is being considered.

Photosensitivity and sensitizing medications

Screen for photosensitivity caused by:

Collagen vascular disease.
Phototoxic or photoallergic medications.
Other conditions that may increase susceptibility to thermal or light injury.

The causative condition or medication may need to be stabilized or discontinued when medically appropriate before treatment.

Impaired healing and eyelid-related risk

Diabetes, heavy smoking, poor wound healing, prior deep resurfacing, and prior lower blepharoplasty may increase complications.

For periorbital treatment, eyelid laxity or prior surgery can increase the risk of tissue contraction and ectropion.

What Is Not a Contraindication but Still Requires Planning

Antiviral prophylaxis

A history of HSV, especially with perioral or full-face treatment, should prompt prophylactic oral antiviral therapy according to local protocol.

This is a risk-management measure, not generally a reason to exclude an otherwise suitable patient.

Antibacterial prophylaxis

Antibacterial prophylaxis may be considered for selected patients or treatment protocols, but it does not replace screening for active infection or sterile wound care.

Treatment depth and bleeding risk

Greater ablation depths increase tissue injury and procedural risk. The cited thresholds—approximately >400 μm for CO₂ and >200 μm for Er:YAG—should be interpreted as prompts for additional procedural planning and hemostasis assessment, not as standalone contraindications.

Understanding the Trade-offs

Contraindication categories vary

The precise classification of isotretinoin use, active infection, keloid tendency, pregnancy, and immune disease varies among laser protocols and professional guidelines.

Clinicians should therefore distinguish between a hard exclusion, a condition requiring deferral, and a factor that permits treatment only with modified settings and enhanced monitoring.

Screening is not limited to disease history

A safe assessment should also cover medication exposure, prior procedures, smoking, diabetes, immune status, HSV history, phototype, wound-care reliability, sun exposure, and expectations.

Unrealistic expectations or inability to comply with postoperative care can make an otherwise medically suitable patient an inappropriate candidate.

Making the Right Choice for Your Goal

The screening decision should be documented as proceed, defer, modify, or exclude, rather than reduced to a simple checklist.

If your primary focus is preventing severe scarring: Exclude patients with facial keloid history and carefully assess hypertrophic-scar history and recent oral retinoid use.
If your primary focus is preventing infection: Defer treatment for active bacterial, viral, or fungal infection and arrange HSV prophylaxis when indicated.
If your primary focus is minimizing pigmentary complications: Assess phototype, prior dyschromia, photosensitizing conditions or medications, and the patient’s ability to maintain strict sun protection.
If your primary focus is safe wound healing: Evaluate immunosuppression, systemic vasculitis, connective-tissue disease, prior radiation, diabetes, smoking, and previous eyelid or resurfacing procedures.

Ablative fractional resurfacing is safest when abnormal scarring, active infection, impaired healing, recent retinoid exposure, and postoperative nonadherence have been identified before treatment begins.

Summary Table:

Contraindication Type	Condition	Action
Absolute	History of facial keloid scarring	Exclude patient
Absolute (protocol-dependent)	Active infection in treatment area	Defer until resolved
Absolute (protocol-dependent)	Current or recent systemic isotretinoin use	Defer for 6-12 months or per protocol
Relative	Active infection in treatment zone	Treat infection first
Relative	Vitiligo or psoriasis	Avoid during active disease; caution if controlled
Relative	Systemic vasculitis or connective tissue disease	Individualized medical assessment
Relative	Active immunosuppression	Review medication and degree; may modify or avoid
Relative	Prior radiation therapy to site	Conservative approach or avoid
Relative	Recent systemic oral retinoid use	Delay 6-12 months or as per protocol
Relative	Darker skin types (IV-VI) or history of dyschromia	Conservative settings; test spot; strict photoprotection
Relative	Pregnancy and breastfeeding	Defer elective treatment
Relative	Photosensitivity or sensitizing medications	Stabilize or discontinue if possible
Relative	Impaired healing (diabetes, smoking)	Assess risk; modify approach
Relative	Prior eyelid surgery or deep resurfacing	Beware of ectropion; adjust periorbital treatment

Maximize patient safety and treatment efficacy with BELIS's advanced laser systems. Our professional-grade medical aesthetic devices are trusted by clinics and premium salons worldwide. With a full spectrum of technology—including fractional CO2, Erbium, and our proven ablative platforms—you can deliver precise, effective resurfacing while confidently managing contraindications. Partner with BELIS for superior equipment, comprehensive training, and dedicated support. Contact us today to explore our OEM/ODM options, certifications, and supply reliability. Get in touch with our experts now and elevate your practice with BELIS!